tgDCC-E1A gene therapy - Targeted Genetics
Alternative Names: E1A gene therapy; HER-2/neu inhibitor; LF 160519; RGG 0853Latest Information Update: 14 Mar 2008
At a glance
- Originator Targeted Genetics
- Developer Targeted Genetics; Targeted Genetics Corporation
- Class Antineoplastics; Gene therapies
- Mechanism of Action ERBB 2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Breast cancer; Head and neck cancer; Ovarian cancer
Most Recent Events
- 14 Aug 2002 Suspended - Phase-I for Ovarian cancer in USA (Intratumoural)
- 07 Aug 2002 Suspended - Phase-I for Ovarian cancer in Europe (Intratumoural)
- 07 Aug 2002 Suspended - Phase-II for Head and neck cancer in USA (Intratumoural)